查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1830147

风湿病药物市场按治疗层级、分子类型、适应症、给药途径、患者年龄层和分销管道划分—全球预测 2025-2032

Rheumatology Therapeutics Market by Therapeutic Class, Molecule Type, Indication, Route Of Administration, Patient Age Group, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，风湿病治疗市场将成长至 558.8 亿美元，复合年增长率为 6.70%。

主要市场统计数据
基准年2024年 332.4亿美元
预计2025年 354.5亿美元
预测年份：2032年 558.8亿美元
复合年增长率（%） 6.70%

不断发展的治疗格局正在再形成风湿病治疗途径的临床实践、付款人期望和商业策略

由于科学创新、监管环境的变化以及患者和付款人行为的转变，风湿病治疗领域正在迅速演变。免疫学和分子药理学的进步持续改变治疗方案，使其从传统的缓解疾病药物扩展到生物目标、生物相似药以及有望实现差异化疗效和安全性的下一代小分子药物。同时，相关人员对真实世界证据、耐受性和长期疗效的期望正在改变新疗法的评估和应用方式。

临床医生和医疗保健系统正在透过重新思考治疗流程和治疗顺序来适应更多样化的治疗方法，重点在于能够兼顾疾病表型和合併症的精准治疗。药物开发和采购组织越来越关注医疗保健价值框架和医疗保健总成本，而製造商则面临着制定更完善的卫生经济学文件并考虑创新合约模式的挑战。因此，商业策略必须在科学差异化与给药途径、依从性和供应链弹性等实际考量之间取得平衡。

展望未来，转化研究、适应症的扩展以及生物相似药市场的日趋成熟将继续影响处方模式和临床指南。因此，整合临床、监管和商业资讯的相关人员将更有能力抓住机会、降低风险，并调整其产品组合，以满足患者需求和系统层面的优先事项。

科学创新、监管日益严格、生物相似药竞争和数数位化证据产生的融合将改变风湿病药物的开发和商业化

多项变革性变化正在汇聚，重新定义风湿病药物，并改变其开发、评估和给药方式。首先，标靶治疗的加速发展和免疫调节机制的完善，正在增加可行的治疗途径，并鼓励临床医生采用更个人化的治疗流程。在这种科学多样化的同时，监管机构更加重视比较疗效、患者报告结果和风险缓解策略，从而对产品上市和整个生命週期的证据要求也更高。

其次，生物相似药的扩张和小分子JAK抑制剂的成熟改变了竞争格局，现有企业和新参与企业都在寻求新的差异化策略，例如改进安全性、便捷的给药途径和整合的病患支援服务。第三，数位化健康工具和分散式试验方法正在增强病人参与，并加速真实世界数据的收集。

第四，在全球疫情爆发暴露出生技药品生产和分销环节的脆弱性后，供应链韧性和生产弹性已成为策略重点。最后，不断发展的报销模式和基于价值的医疗服务计划正在影响定价和合约签订方式，激励製造商展示长期效益并考虑与结果挂钩的合约。这些转变需要一种奖励的产品开发和商业化方法，将科学创新与证据生成、相关人员参与和营运敏捷性结合起来。

到 2025 年，关税主导的供应链转变和控製成本的需求累积迫使製造商重新调整其采购、生产和定价策略

预计2025年的关税环境和贸易政策调整将为整个医药价值链带来新的成本和供应动态，尤其对风湿病药物产业的影响。关税可能会影响原材料采购、生技药品生产投入以及成品分销，从而可能增加供应链中多个节点的成本压力。製造商正在采取应对措施，包括重新审视供应商关係、实现製造地多元化以及加快本地产能建设，以减轻关税影响并保持定价弹性。

此外，与关税相关的成本波动可能会影响关于灌装-表面处理工程位置、委託製造伙伴关係以及库存管理方法的策略决策。这些营运变化通常会对时间和资本产生影响，迫使公司优先考虑能够减少对高关税地区依赖的生产能力。此外，付款人和采购组织可能会仔细审查贸易措施导致的价格调整，因此更重视透明的成本核算模型和证明价格变动相对于临床价值合理性的有力证据。

最后，关税的累积影响将与生物相似药进入市场和竞争性定价压力等更广泛的趋势相互交织，共同塑造谈判动态和准入策略。积极模拟关税情景、增强供应商多元化、并向付款人和医疗保健提供者清晰传达其价值提案的公司，将在新的贸易体制下占据有利地位，从而保持市场准入并保护利润。

综合细分洞察揭示了治疗层级、分子类型、适应症、给药途径、年龄层和管道动态，这些因素决定了策略重点

我们主导细分市场的分析揭示了治疗层级、分子类型、适应症、给药途径、患者人口统计和分销管道的产品差异化和商业化路径的细微差别。依照治疗层级，我们研究了传统的抗风湿性关节炎 (DMARD)、IL-6 抑制剂、JAK 抑制剂和 TNF 抑制剂，以及羟氯喹、来氟米特、胺基甲基叶酸和柳氮磺吡啶等传统抗风湿性关节炎 (DMARD)。这种细分揭示了临床熟悉度和长期安全性如何与标靶药物旨在解决的未满足需求相互交织。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 将真实世界数据与人工智慧驱动的分析相结合，以优化类风湿性关节炎患者的生物疗法选择
  • 生物相似药互换性指南的推出加速了风湿病领域TNF抑制剂的经济有效获取
  • 针对新出现的心血管和癌症风险数据开发 JAK 抑制剂安全监测通讯协定
  • 实施患者报告结果数位平台，以个人化慢性自体免疫疾病的治疗依从性
  • 标靶小分子设计的进展将助力难治性干癣性关节炎的下一代治疗
  • 新型 IL-17 和 IL-23 抑制剂已获监管部门核准，改善中轴型脊椎关节炎的治疗流程

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 风湿病药物市场（依治疗层级）

  • 传统需求
    • 羟氯喹
    • 来氟米特
    • 胺基甲基叶酸
    • 柳氮磺吡啶
  • IL-6抑制剂
  • Jak抑制剂
  • TNF抑制剂

9. 类风湿性关节炎药物市场（依分子型态）

  • 生物製药
  • 生物相似药
  • 小分子

第十章风湿病药物市场（依适应症）

  • 僵直性脊椎炎
  • 痛风
  • 干癣性关节炎
  • 类风湿性关节炎
  • 全身性红斑性狼疮

第11章风湿病药物市场（依给药途径）

  • 静脉
  • 口服
  • 皮下

第十二章 风湿病治疗市场（依患者年龄层）

  • 成人
  • 孩子们

第十三章风湿病药物市场（依通路）

  • 离线
  • 在线的

第十四章风湿病药物市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 15 章风湿病药物市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国风湿病药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • AbbVie Inc.
    • Johnson & Johnson
    • Novartis AG
    • Roche Holding AG
    • Pfizer Inc.
    • Amgen Inc.
    • Eli Lilly and Company
    • Sanofi SA
    • Bristol-Myers Squibb Company
    • UCB SA
Product Code: MRR-437896AA372B

The Rheumatology Therapeutics Market is projected to grow by USD 55.88 billion at a CAGR of 6.70% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 33.24 billion
Estimated Year [2025] USD 35.45 billion
Forecast Year [2032] USD 55.88 billion
CAGR (%) 6.70%

An evolving therapeutic environment reshaping clinical practice, payer expectations, and commercial strategies across rheumatology care pathways

The rheumatology therapeutics landscape is experiencing a period of rapid evolution driven by scientific innovation, shifting regulatory expectations, and changing patient and payer behaviors. Advances in immunology and molecular pharmacology continue to reframe therapeutic options, expanding beyond conventional disease-modifying agents into targeted biologics, biosimilars, and next-generation small molecules that promise differentiated efficacy and safety profiles. At the same time, stakeholder expectations around real-world evidence, tolerability, and long-term outcomes are reshaping how new assets are evaluated and adopted.

Clinicians and health systems are responding to a more diversified armamentarium by rethinking treatment algorithms and sequencing, with a greater emphasis on precision approaches that consider disease phenotype and comorbidity. Payers and procurement entities are intensifying focus on value frameworks and total cost of care, prompting manufacturers to develop more robust health economic dossiers and to consider innovative contracting models. Consequently, commercial strategies must balance scientific differentiation with pragmatic considerations like administration route, adherence, and supply chain resilience.

Looking ahead, translational research, expanded indications, and the maturation of biosimilar markets will continue to influence prescribing patterns and clinical guidelines. As a result, stakeholders who integrate clinical, regulatory, and commercial intelligence will be best positioned to capture opportunities, mitigate risks, and align portfolios to meet both patient needs and system-level priorities.

Converging scientific innovation, regulatory rigor, biosimilar competition, and digital-enabled evidence generation transforming rheumatology therapeutic development and commercialization

Several transformative shifts are converging to redefine rheumatology therapeutics, altering how therapies are developed, evaluated, and delivered. First, the acceleration of targeted modalities and the refinement of immunomodulatory mechanisms have increased the number of viable therapeutic pathways, prompting clinicians to adopt more personalized treatment algorithms. Alongside this scientific diversification, regulatory authorities are placing growing emphasis on comparative effectiveness, patient-reported outcomes, and risk mitigation strategies, resulting in richer evidence requirements at launch and over a product's lifecycle.

Second, the expansion of biosimilars and the maturation of small-molecule JAK inhibitors have recalibrated competitive dynamics, encouraging incumbents and newcomers to pursue novel differentiation strategies such as improved safety profiles, convenient administration routes, and integrated patient support services. Third, digital health tools and decentralized trial methodologies are enhancing patient engagement and accelerating data capture in real-world settings, which in turn inform payer negotiations and clinical guideline revisions.

Fourth, supply chain resilience and manufacturing flexibility have become strategic priorities after global disruptions revealed vulnerabilities in biologics production and distribution. Finally, evolving reimbursement models and value-based care pilots are influencing pricing and contracting approaches, incentivizing manufacturers to demonstrate longitudinal benefits and to consider outcome-linked agreements. Together, these shifts necessitate an integrated approach to product development and commercialization that aligns scientific innovation with evidence generation, stakeholder engagement, and operational agility.

Cumulative tariff-driven supply chain shifts and cost management imperatives will compel manufacturers to realign sourcing, production, and pricing strategies by 2025

The incoming tariff environment and trade policy adjustments scheduled for implementation in 2025 are poised to introduce new cost and supply dynamics across pharmaceutical value chains, with specific implications for rheumatology therapeutics. Tariffs can affect raw material sourcing, biologics manufacturing inputs, and finished goods distribution, which may increase cost pressures at multiple nodes of the supply chain. Manufacturers are responding by reassessing supplier relationships, diversifying manufacturing footprints, and accelerating local production capabilities to mitigate tariff exposure and to preserve pricing flexibility.

Moreover, tariff-related cost volatility can influence strategic decisions about the location of fill-and-finish operations, contract manufacturing partnerships, and inventory management practices. These operational shifts often carry timing and capital implications, compelling organizations to prioritize capacity that reduces dependence on high-tariff corridors. In addition, payers and procurement bodies are likely to scrutinize pricing adjustments driven by trade measures, which places a premium on transparent costing models and robust evidence that justifies price changes in the context of clinical value.

Finally, the cumulative impact of tariffs intersects with broader trends such as biosimilar entry and competitive pricing pressures, which together will shape negotiation dynamics and access strategies. Companies that proactively model tariff scenarios, strengthen supplier diversification, and communicate value propositions clearly to payers and providers will be better positioned to preserve access and protect margins under the new trade regime.

Integrated segmentation insight reveals therapeutic class, molecule type, indication, administration route, age cohort, and channel dynamics shaping strategic priorities

Segmentation-driven analysis reveals nuanced pathways for product differentiation and commercialization across therapeutic class, molecule type, indication, route of administration, patient age group, and distribution channel. Based on therapeutic class, the landscape is studied across Conventional DMARDs, IL-6 inhibitors, JAK inhibitors, and TNF inhibitors, with Conventional DMARDs further examined across hydroxychloroquine, leflunomide, methotrexate, and sulfasalazine. This granularity clarifies where clinical familiarity and long-standing safety profiles intersect with unmet needs that targeted agents seek to address.

Based on molecule type, the landscape is studied across biologics, biosimilars, and small molecules, a classification that highlights manufacturing complexity, regulatory pathways, and cost-to-patient considerations. Based on indication, the landscape is studied across ankylosing spondylitis, gout, psoriatic arthritis, rheumatoid arthritis, and systemic lupus erythematosus, enabling indication-specific strategies that align clinical endpoints and patient outcomes with formulary positioning. Based on route of administration, the landscape is studied across intravenous, oral, and subcutaneous options, which directly influence adherence, site-of-care economics, and patient preference.

Based on patient age group, the landscape is studied across adult and pediatric populations, drawing attention to dosing, safety, and trial design considerations that differ by cohort. Based on distribution channel, the landscape is studied across offline and online pathways, underscoring the importance of omnichannel engagement and supply chain agility. Across these intersecting segmentation axes, manufacturers and stakeholders can identify pockets of clinical differentiation, prioritize evidence generation for the most relevant endpoints, and tailor commercialization plans to the nuanced needs of clinicians, patients, and payers.

Regional differentiation in access, reimbursement, and adoption across the Americas, Europe Middle East & Africa, and Asia-Pacific requires bespoke commercialization strategies

Regional dynamics will continue to shape access, adoption, and commercialization approaches in rheumatology therapeutics, with distinct drivers across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, a combination of advanced clinical infrastructure, centralized research networks, and payer-driven value assessments influences the speed of adoption for novel therapies and the design of outcomes-based agreements. Stakeholders in this region often prioritize head-to-head evidence, long-term safety data, and pragmatic real-world effectiveness studies to support formulary decisions and guideline integration.

In Europe, Middle East & Africa, the interplay of national reimbursement systems, regional procurement mechanisms, and heterogeneous regulatory environments creates both challenges and opportunities for differentiated products. Manufacturers must navigate varied HTA thresholds, pricing controls, and tender processes while leveraging localized evidence generation and partnership models to secure access. In the Asia-Pacific region, rapid investment in biologics manufacturing capacity, growing clinical trial activity, and expanding healthcare spending are driving both demand for innovative therapies and price sensitivity that favors biosimilars and cost-efficient modalities.

Across all regions, supply chain resilience, local regulatory engagement, and culturally attuned patient support programs are critical for successful market entry and sustainable adoption. Therefore, regional strategies need to be bespoke, balancing global clinical evidence with localized implementation plans that reflect reimbursement frameworks, provider practices, and patient expectations.

Competitive landscape shaped by biologic innovators, biosimilar entrants, and agile small-molecule developers driving strategic partnerships and lifecycle differentiation

Competitive dynamics across the rheumatology landscape are shaped by innovators with differentiated biologics, established small-molecule franchises, and an expanding cohort of biosimilar entrants. Leading developers of biologic therapies continue to invest in lifecycle strategies, pursuing indication expansions and improved formulations that enhance convenience or tolerability. At the same time, manufacturers of small molecules are focusing on safety profile optimization and label differentiation to maintain relevance against biologic competition.

The rise of biosimilars has introduced new procurement behaviors and pricing benchmarks, prompting originator companies to emphasize service offerings, patient support, and evidence demonstrating long-term outcomes. Strategic collaborations between specialty pharmaceutical firms and contract manufacturing organizations have also intensified, as companies seek to secure commercial supply and scale manufacturing efficiently. In parallel, smaller biotech and specialty companies are leveraging focused clinical development programs and nimble commercial approaches to target niche indications and subpopulations where unmet need remains high.

Taken together, these dynamics create a competitive ecosystem where product differentiation, evidentiary depth, supply reliability, and stakeholder engagement determine commercial success. Companies that align clinical development with clear value propositions and robust support infrastructures will be best positioned to sustain uptake amid increasing therapeutic choice.

Actionable strategic initiatives for leaders to integrate clinical differentiation, evidence generation, supply resilience, and flexible contracting for sustained commercial advantage

Industry leaders should adopt a multi-dimensional strategy that integrates scientific differentiation, evidence generation, and operational resilience to capture long-term value in rheumatology therapeutics. First, prioritize clinical programs that demonstrate meaningful improvements in patient-reported outcomes and long-term safety, and align trial endpoints with payer and guideline expectations to reduce barriers to uptake. Second, invest in robust real-world evidence platforms and digital health initiatives that can validate effectiveness in routine practice and support value-based contracting conversations.

Third, strengthen supply chain resilience by diversifying sourcing, exploring regional manufacturing partnerships, and optimizing inventory strategies to mitigate tariff and trade-related disruptions. Fourth, tailor commercial models to route-of-administration preferences and care settings, offering convenience-oriented solutions such as subcutaneous formulations, patient support services, and hub models that ease administration and adherence. Fifth, adopt flexible pricing and contracting approaches, including outcome-based agreements where appropriate, to address payer demands for transparency and performance linkage.

Finally, cultivate collaborative engagement with clinicians, payers, and patient organizations to co-design access pathways and to ensure that evidence generation remains relevant to real-world decision-making. By executing these interlocking initiatives, leaders can both accelerate adoption of differentiated therapies and build durable competitive advantages.

A mixed-methods evidence synthesis integrating clinical literature, regulatory guidance, expert interviews, and scenario-based supply chain analysis to inform strategy

The research underpinning this analysis employs a mixed-methods approach that synthesizes peer-reviewed literature, regulatory documentation, clinical trial registries, public policy announcements, and industry disclosures to generate a comprehensive view of therapeutic and commercial dynamics. Primary qualitative inputs include interviews with clinicians, payers, and industry experts to validate interpretation of clinical priorities, reimbursement considerations, and operational constraints. Secondary analysis consolidates regulatory guidance, published trial results, and public domain lifecycle activities to identify trends in therapeutic development and evidence needs.

Analytical techniques combine thematic synthesis for qualitative insights with scenario analysis to evaluate the operational implications of trade and policy shifts. Evidence triangulation ensures that conclusions are robust across multiple data sources and stakeholder perspectives, while sensitivity checks assess the resilience of strategic recommendations under varied assumptions. Throughout the research process, emphasis was placed on aligning clinical endpoints and real-world outcome measures with payer and guideline criteria to ensure relevance for commercialization planning.

This methodology supports transparent, actionable insights by linking clinical innovation to regulatory, payer, and supply chain realities, thereby enabling stakeholders to translate evidence into concrete tactical and strategic decisions.

Converging scientific, regulatory, and commercial trends demand integrated evidence-led strategies and operational resilience across rheumatology therapeutic value chains

In summary, the rheumatology therapeutics landscape is undergoing a substantive transformation driven by scientific advances, evolving regulatory expectations, competitive diversity, and shifting commercial imperatives. These forces are redefining what constitutes clinical value, how evidence must be generated and communicated, and how therapies must be delivered to meet both patient needs and system-level efficiency goals. As therapeutic options expand across biologics, biosimilars, and small molecules, stakeholders must reconcile differentiation claims with pragmatic concerns around administration, access, and long-term outcomes.

Operationally, tariff adjustments and supply chain pressures add a further layer of complexity, underscoring the importance of manufacturing flexibility and supplier diversification. Regionally differentiated access pathways and payer frameworks require bespoke strategies that localize global evidence and adapt commercial models to reimbursement realities. To succeed, organizations should integrate clinical development, real-world evidence programs, and commercial operations under a unified strategic framework that emphasizes resilience, stakeholder alignment, and measurable patient benefit.

The coming period will reward those who combine scientific innovation with disciplined evidence generation and agile execution, enabling sustained access and impact for patients living with rheumatologic disease.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of real-world data and AI-driven analytics to optimize biologic therapy selection for rheumatoid arthritis patients
  • 5.2. Emergence of biosimilar interchangeability guidelines accelerating cost-effective access to TNF inhibitors in rheumatology
  • 5.3. Development of JAK inhibitor safety monitoring protocols in response to emerging cardiovascular and malignancy risk data
  • 5.4. Adoption of patient-reported outcome digital platforms to personalize treatment adherence in chronic autoimmune disorders
  • 5.5. Advances in targeted small molecule design enabling next-generation therapies for refractory psoriatic arthritis cases
  • 5.6. Regulatory approvals of novel IL-17 and IL-23 inhibitors reshaping treatment algorithms in axial spondyloarthritis management

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Rheumatology Therapeutics Market, by Therapeutic Class

  • 8.1. Conventional Dmards
    • 8.1.1. Hydroxychloroquine
    • 8.1.2. Leflunomide
    • 8.1.3. Methotrexate
    • 8.1.4. Sulfasalazine
  • 8.2. Il-6 Inhibitors
  • 8.3. Jak Inhibitors
  • 8.4. Tnf Inhibitors

9. Rheumatology Therapeutics Market, by Molecule Type

  • 9.1. Biologics
  • 9.2. Biosimilars
  • 9.3. Small Molecules

10. Rheumatology Therapeutics Market, by Indication

  • 10.1. Ankylosing Spondylitis
  • 10.2. Gout
  • 10.3. Psoriatic Arthritis
  • 10.4. Rheumatoid Arthritis
  • 10.5. Systemic Lupus Erythematosus

11. Rheumatology Therapeutics Market, by Route Of Administration

  • 11.1. Intravenous
  • 11.2. Oral
  • 11.3. Subcutaneous

12. Rheumatology Therapeutics Market, by Patient Age Group

  • 12.1. Adult
  • 12.2. Pediatric

13. Rheumatology Therapeutics Market, by Distribution Channel

  • 13.1. Offline
  • 13.2. Online

14. Rheumatology Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Rheumatology Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Rheumatology Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. AbbVie Inc.
    • 17.3.2. Johnson & Johnson
    • 17.3.3. Novartis AG
    • 17.3.4. Roche Holding AG
    • 17.3.5. Pfizer Inc.
    • 17.3.6. Amgen Inc.
    • 17.3.7. Eli Lilly and Company
    • 17.3.8. Sanofi S.A.
    • 17.3.9. Bristol-Myers Squibb Company
    • 17.3.10. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. RHEUMATOLOGY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. RHEUMATOLOGY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. RHEUMATOLOGY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY LEFLUNOMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY LEFLUNOMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY LEFLUNOMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY LEFLUNOMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY LEFLUNOMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY LEFLUNOMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SULFASALAZINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SULFASALAZINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SULFASALAZINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SULFASALAZINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SULFASALAZINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SULFASALAZINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY IL-6 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY IL-6 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY IL-6 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY IL-6 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY IL-6 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY IL-6 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY BIOSIMILARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY BIOSIMILARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY BIOSIMILARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY BIOSIMILARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY BIOSIMILARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GOUT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GOUT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GOUT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GOUT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GOUT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GOUT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 305. GCC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. GCC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLI